Health
Novartis drug pacibekitug reduces inflammation markers in Phase 2 trial
Results from the midstage study show dose-dependent reductions in inflammation biomarkers as researchers evaluate its potential for cardiovascular treatment.
The short version
- Novartis presented Phase 2 trial results for pacibekitug at the European Society of Cardiology annual meeting.
- The drug successfully lowered inflammation biomarkers in a sustained, dose-dependent manner.
- It remains unknown how Novartis plans to advance the drug into future trials for cardiovascular outcomes.
Key facts
- Novartis presented results from its Phase 2 TRANQUILITY trial for pacibekitug at the European Society of Cardiology annual meeting in Munich.[STAT]
- Pacibekitug is an antibody targeting interleukin-6 (IL-6), a protein involved in immune system regulation.[STAT]
- Trial investigators observed sustained, dose-dependent decreases in key inflammation biomarkers, with higher doses yielding greater reductions.[STAT]
What remains uncertain
- It is not yet detailed how Novartis intends to design or advance future clinical trials evaluating pacibekitug for cardiovascular outcomes.[STAT]